| Market Cap | 4.54M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -30.17M | Forward P/E | 38.33 | EPS next Y | - | 50D Avg Chg | -31.00% |
| Sales | 3.71M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -85.00% |
| Dividend | N/A | Price/Book | 1.34 | EPS next 5Y | - | 52W High Chg | -97.00% |
| Recommedations | 2.00 | Quick Ratio | 0.39 | Shares Outstanding | 1.28M | 52W Low Chg | 7.00% |
| Insider Own | - | ROA | -44.88% | Shares Float | 11.09B | Beta | 3.67 |
| Inst Own | 11.53% | ROE | -1,708.61% | Shares Shorted/Prior | 49.76K/21.66K | Price | 1.15 |
| Gross Margin | 34.04% | Profit Margin | - | Avg. Volume | 208,872 | Target Price | 19,000.00 |
| Oper. Margin | -328.46% | Earnings Date | Aug 29 | Volume | 390,920 | Change | -8.00% |
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
